ArticleAnnals of hematology2022

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.

Kathrin Rieger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.